• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SCHEDULE 13G/A filed by CG Oncology Inc.

    1/28/25 5:08:33 PM ET
    $CGON
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $CGON alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    (Amendment No. 1)


    CG Oncology, Inc.

    (Name of Issuer)


    Common stock, $0.0001 par value per share

    (Title of Class of Securities)


    156944100

    (CUSIP Number)


    12/31/2024

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox not checked   Rule 13d-1(b)
    Checkbox not checked   Rule 13d-1(c)
    Checkbox checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    156944100


    1Names of Reporting Persons

    Unique Diamond Investments Limited
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    VIRGIN ISLANDS, BRITISH
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    586,982.00
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    586,982.00
    8Shared Dispositive Power

    0.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    586,982.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    0.8 %
    12Type of Reporting Person (See Instructions)

    CO

    Comment for Type of Reporting Person:  *This calculation is based on 76,037,858 shares of Common stock, $0.0001 par value per share ("Common Stock") outstanding as of December 16, 2024, as disclosed in the Issuer's Form 424B4 Prospectus filed by the Company on December 13, 2024 based on the number of shares of Common Stock to be outstanding if the underwriters exercised their option to purchase additional shares of Common Stock in full.


    SCHEDULE 13G

    CUSIP No.
    156944100


    1Names of Reporting Persons

    ORI Healthcare Fund, L.P.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    CAYMAN ISLANDS
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    586,982.00
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    586,982.00
    8Shared Dispositive Power

    0.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    586,982.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    0.8 %
    12Type of Reporting Person (See Instructions)

    PN

    Comment for Type of Reporting Person:  *This calculation is based on 76,037,858 shares of Common Stock outstanding as of December 16, 2024, as disclosed in the Issuer's Form 424B4 Prospectus filed by the Company on December 13, 2024 based on the number of shares of Common Stock to be outstanding if the underwriters exercised their option to purchase additional shares of Common Stock in full.


    SCHEDULE 13G

    CUSIP No.
    156944100


    1Names of Reporting Persons

    ORI Capital Inc.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    CAYMAN ISLANDS
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    586,982.00
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    586,982.00
    8Shared Dispositive Power

    0.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    586,982.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    0.8 %
    12Type of Reporting Person (See Instructions)

    CO

    Comment for Type of Reporting Person:  *This calculation is based on 76,037,858 shares of Common Stock outstanding as of December 16, 2024, as disclosed in the Issuer's Form 424B4 Prospectus filed by the Company on December 13, 2024 based on the number of shares of Common Stock to be outstanding if the underwriters exercised their option to purchase additional shares of Common Stock in full.


    SCHEDULE 13G

    CUSIP No.
    156944100


    1Names of Reporting Persons

    ORI Capital Holding Inc.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    CAYMAN ISLANDS
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    586,982.00
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    586,982.00
    8Shared Dispositive Power

    0.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    586,982.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    0.8 %
    12Type of Reporting Person (See Instructions)

    CO

    Comment for Type of Reporting Person:  *This calculation is based on 76,037,858 shares of Common Stock outstanding as of December 16, 2024, as disclosed in the Issuer's Form 424B4 Prospectus filed by the Company on December 13, 2024 based on the number of shares of Common Stock to be outstanding if the underwriters exercised their option to purchase additional shares of Common Stock in full.


    SCHEDULE 13G

    CUSIP No.
    156944100


    1Names of Reporting Persons

    Charming Jade Limited
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    VIRGIN ISLANDS, BRITISH
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    3,003,931.00
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    3,003,931.00
    8Shared Dispositive Power

    0.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    3,003,931.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    4 %
    12Type of Reporting Person (See Instructions)

    CO

    Comment for Type of Reporting Person:  *This calculation is based on 76,037,858 shares of Common Stock outstanding as of December 16, 2024, as disclosed in the Issuer's Form 424B4 Prospectus filed by the Company on December 13, 2024 based on the number of shares of Common Stock to be outstanding if the underwriters exercised their option to purchase additional shares of Common Stock in full.


    SCHEDULE 13G

    CUSIP No.
    156944100


    1Names of Reporting Persons

    ORI Healthcare Fund II, L.P.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    CAYMAN ISLANDS
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    3,003,931.00
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    3,003,931.00
    8Shared Dispositive Power

    0.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    3,003,931.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    4 %
    12Type of Reporting Person (See Instructions)

    PN

    Comment for Type of Reporting Person:  *This calculation is based on 76,037,858 shares of Common Stock outstanding as of December 16, 2024, as disclosed in the Issuer's Form 424B4 Prospectus filed by the Company on December 13, 2024 based on the number of shares of Common Stock to be outstanding if the underwriters exercised their option to purchase additional shares of Common Stock in full.


    SCHEDULE 13G

    CUSIP No.
    156944100


    1Names of Reporting Persons

    ORI Capital II Inc.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    CAYMAN ISLANDS
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    3,003,931.00
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    3,003,931.00
    8Shared Dispositive Power

    0.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    3,003,931.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    4 %
    12Type of Reporting Person (See Instructions)

    CO

    Comment for Type of Reporting Person:  *This calculation is based on 76,037,858 shares of Common Stock outstanding as of December 16, 2024, as disclosed in the Issuer's Form 424B4 Prospectus filed by the Company on December 13, 2024 based on the number of shares of Common Stock to be outstanding if the underwriters exercised their option to purchase additional shares of Common Stock in full.


    SCHEDULE 13G

    CUSIP No.
    156944100


    1Names of Reporting Persons

    ORI Holding II Inc.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    CAYMAN ISLANDS
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    3,003,931.00
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    3,003,931.00
    8Shared Dispositive Power

    0.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    3,003,931.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    4 %
    12Type of Reporting Person (See Instructions)

    CO

    Comment for Type of Reporting Person:  *This calculation is based on 76,037,858 shares of Common Stock outstanding as of December 16, 2024, as disclosed in the Issuer's Form 424B4 Prospectus filed by the Company on December 13, 2024 based on the number of shares of Common Stock to be outstanding if the underwriters exercised their option to purchase additional shares of Common Stock in full.


    SCHEDULE 13G

    CUSIP No.
    156944100


    1Names of Reporting Persons

    Healthcare Seed Limited
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    CAYMAN ISLANDS
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    3,590,913.00
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    3,590,913.00
    8Shared Dispositive Power

    0.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    3,590,913.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    4.7 %
    12Type of Reporting Person (See Instructions)

    CO

    Comment for Type of Reporting Person:  *This calculation is based on 76,037,858 shares of Common Stock outstanding as of December 16, 2024, as disclosed in the Issuer's Form 424B4 Prospectus filed by the Company on December 13, 2024 based on the number of shares of Common Stock to be outstanding if the underwriters exercised their option to purchase additional shares of Common Stock in full.


    SCHEDULE 13G

    CUSIP No.
    156944100


    1Names of Reporting Persons

    SONG, Hong Fang
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    HONG KONG
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    4,211,341.00
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    4,211,341.00
    8Shared Dispositive Power

    0.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    4,211,341.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    5.5 %
    12Type of Reporting Person (See Instructions)

    IN

    Comment for Type of Reporting Person:  *This calculation is based on 76,037,858 shares of Common Stock outstanding as of December 16, 2024, as disclosed in the Issuer's Form 424B4 Prospectus filed by the Company on December 13, 2024 based on the number of shares of Common Stock to be outstanding if the underwriters exercised their option to purchase additional shares of Common Stock in full.


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    CG Oncology, Inc.
    (b)Address of issuer's principal executive offices:

    400 Spectrum Center Drive, Suite 2040, Irvine, California, 92618
    Item 2. 
    (a)Name of person filing:

    Unique Diamond Investments Limited Charming Jade Limited ORI Healthcare Fund, L.P. ORI Healthcare Fund II, L.P. ORI Capital Inc. ORI Capital II Inc. ORI Capital Holding Inc. ORI Holding II Inc. Healthcare Seed Limited SONG, Hong Fang Unique Diamond Investments Limited is a wholly owned subsidiary of ORI Healthcare Fund, L.P. ORI Capital Inc. is the general partner of ORI Healthcare Fund, L.P. and a wholly owned subsidiary of ORI Capital Holding Inc. Charming Jade Limited is a wholly owned subsidiary of ORI Healthcare Fund II, L.P. ORI Capital II Inc. is the general partner of ORI Healthcare Fund II, L.P. and a wholly owned subsidiary of ORI Holding II Inc. Each of ORI Capital Holding Inc. and ORI Holding II Inc. is a wholly owned subsidiary of Healthcare Seed Limited. Ms. Song is the sole owner of Healthcare Seed Limited. Each of the foregoing parties is referred to as a "Reporting Person" and collectively, as the "Reporting Persons."
    (b)Address or principal business office or, if none, residence:

    The principal business office of each of the Reporting Persons is C/O Room Nos., 4727-34, Sun Hung Kai Centre, 30 Harbour Road, Wanchai, Hong Kong.
    (c)Citizenship:

    The citizenship or place of organization of each of the Reporting Persons is set forth on such Reporting Person's cover page.
    (d)Title of class of securities:

    Common stock, $0.0001 par value per share
    (e)CUSIP No.:

    156944100
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox not checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    The information set forth in rows 5 through 11 of the cover pages to this Schedule 13G is incorporated by reference. The reported percentages are based upon 76,037,858 shares of Common Stock outstanding as of December 16, 2024, as disclosed in the Issuer's Form 424B4 Prospectus filed by the Company on December 13, 2024 based on the number of shares of Common Stock to be outstanding if the underwriters exercised their option to purchase additional shares of Common Stock in full. Unique Diamond Investments Limited directly owns 586,982 shares of Common Stock, which represents approximately 0.8% of the outstanding shares of Common Stock, and Charming Jade Limited directly owns 3,003,931 shares of Common Stock, which represents approximately 4.0% of the outstanding shares of Common Stock. Unique Diamond Investments Limited is a wholly-owned subsidiary of ORI Healthcare Fund, L.P. ORI Capital Inc. is the general partner of ORI Healthcare Fund, L.P. and may be deemed to have voting, investment and dispositive power with respect to these securities. ORI Capital Inc. is a wholly-owned subsidiary of ORI Capital Holding Inc, which is a wholly-owned subsidiary of Healthcare Seed Limited. Charming Jade Limited is a wholly-owned subsidiary of ORI Healthcare Fund II, L.P. ORI Capital II Inc. is the general partner of ORI Healthcare Fund II, L.P. and may be deemed to have voting, investment and dispositive power with respect to these securities. ORI Capital II Inc. is a wholly-owned subsidiary of ORI Holding II Inc., which is a wholly-owned Subsidiary of Healthcare Seed Limited. Healthcare Seed Limited, as a result, may be deemed to beneficially own 3,590,913 shares of Common Stock held by Unique Diamond Investments Limited and Charming Jade Limited, which represents approximately 4.7% of the outstanding shares of Common Stock. As the sole owner of Healthcare Seed Limited, Ms. Song may be deemed to beneficially own 4,211,341 shares of Common Stock, which includes 613,928 shares of Common Stock held directly by Ms. Song and 6,500 shares of Common Stock underlying options held by Ms. Song that are exercisable as of December 31, 2024 or that will become exercisable within 60 days after such date, which represents approximately 5.5% of the outstanding shares of Common Stock.
    (b)Percent of class:

    See above.
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    (1) Unique Diamond Investments Limited: 586,982 shares of Common Stock; (2) ORI Healthcare Fund, L.P.: 586,982 shares of Common Stock; (3) ORI Capital Inc.: 586,982 shares of Common Stock; (4) ORI Capital Holding Inc.: 586,982 shares of Common Stock; (5) Charming Jade Limited: 3,003,931 shares of Common Stock; (6) ORI Healthcare Fund II, L.P.: 3,003,931 shares of Common Stock; (7) ORI Capital II Inc.: 3,003,931 shares of Common Stock; (8) ORI Holding II Inc.: 3,003,931 shares of Common Stock; (9) Healthcare Seed Limited: 3,590,913 shares of Common Stock; and (10) SONG, Hong Fang: 4,211,341 shares of Common Stock.

     (ii) Shared power to vote or to direct the vote:

    None.

     (iii) Sole power to dispose or to direct the disposition of:

    (1) Unique Diamond Investments Limited: 586,982 shares of Common Stock; (2) ORI Healthcare Fund, L.P.: 586,982 shares of Common Stock; (3) ORI Capital Inc.: 586,982 shares of Common Stock; (4) ORI Capital Holding Inc.: 586,982 shares of Common Stock; (5) Charming Jade Limited: 3,003,931 shares of Common Stock; (6) ORI Healthcare Fund II, L.P.: 3,003,931 shares of Common Stock; (7) ORI Capital II Inc.: 3,003,931 shares of Common Stock; (8) ORI Holding II Inc.: 3,003,931 shares of Common Stock; (9) Healthcare Seed Limited: 3,590,913 shares of Common Stock; and (10) SONG, Hong Fang: 4,211,341 shares of Common Stock.

     (iv) Shared power to dispose or to direct the disposition of:

    None.

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    Not Applicable
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    Not Applicable

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    Unique Diamond Investments Limited
     
    Signature:/s/ SONG, Hong Fang
    Name/Title:SONG, Hong Fang/Director
    Date:01/28/2025
     
    ORI Healthcare Fund, L.P.
     
    Signature:/s/ SONG, Hong Fang
    Name/Title:SONG, Hong Fang/Director
    Date:01/28/2025
     
    ORI Capital Inc.
     
    Signature:/s/ SONG, Hong Fang
    Name/Title:SONG, Hong Fang/Director
    Date:01/28/2025
     
    ORI Capital Holding Inc.
     
    Signature:/s/ SONG, Hong Fang
    Name/Title:SONG, Hong Fang/Director
    Date:01/28/2025
     
    Charming Jade Limited
     
    Signature:/s/ SONG, Hong Fang
    Name/Title:SONG, Hong Fang/Director
    Date:01/28/2025
     
    ORI Healthcare Fund II, L.P.
     
    Signature:/s/ SONG, Hong Fang
    Name/Title:SONG, Hong Fang/Director of General Partner
    Date:01/28/2025
     
    ORI Capital II Inc.
     
    Signature:/s/ SONG, Hong Fang
    Name/Title:SONG, Hong Fang/Director
    Date:01/28/2025
     
    ORI Holding II Inc.
     
    Signature:/s/ SONG, Hong Fang
    Name/Title:SONG, Hong Fang/Director
    Date:01/28/2025
     
    Healthcare Seed Limited
     
    Signature:/s/ SONG, Hong Fang
    Name/Title:SONG, Hong Fang/Director
    Date:01/28/2025
     
    SONG, Hong Fang
     
    Signature:/s/ SONG, Hong Fang
    Name/Title:SONG, Hong Fang
    Date:01/28/2025
    Get the next $CGON alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CGON

    DatePrice TargetRatingAnalyst
    12/11/2025$70.00Outperform
    Wedbush
    11/24/2025Buy
    Truist
    10/8/2025$90.00Buy
    Guggenheim
    8/19/2025$55.00Overweight
    Piper Sandler
    7/10/2025$40.00Buy
    Goldman
    5/2/2025$41.00Overweight
    Analyst
    4/16/2025$23.00Sector Perform
    Scotiabank
    1/7/2025Buy
    TD Cowen
    More analyst ratings

    $CGON
    SEC Filings

    View All

    SEC Form 8-K filed by CG Oncology Inc.

    8-K - CG Oncology, Inc. (0001991792) (Filer)

    1/13/26 4:51:58 PM ET
    $CGON
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 424B5 filed by CG Oncology Inc.

    424B5 - CG Oncology, Inc. (0001991792) (Filer)

    1/13/26 4:47:48 PM ET
    $CGON
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 144 filed by CG Oncology Inc.

    144 - CG Oncology, Inc. (0001991792) (Subject)

    1/9/26 4:32:41 PM ET
    $CGON
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $CGON
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Mulay James sold $584,799 worth of shares (11,145 units at $52.47) and exercised 11,145 shares at a strike of $12.07 (SEC Form 4)

    4 - CG Oncology, Inc. (0001991792) (Issuer)

    1/13/26 4:15:07 PM ET
    $CGON
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 4 filed by Director Rossi Christina

    4 - CG Oncology, Inc. (0001991792) (Issuer)

    11/26/25 4:30:09 PM ET
    $CGON
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 3 filed by new insider Rossi Christina

    3 - CG Oncology, Inc. (0001991792) (Issuer)

    11/26/25 4:15:03 PM ET
    $CGON
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $CGON
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Oncolytics Biotech® Appoints John McAdory as EVP of Strategy and Operations and Yujun Wu to Lead Biostatistics

    SAN DIEGO, Jan. 14, 2026 (GLOBE NEWSWIRE) -- Oncolytics Biotech® Inc. (NASDAQ:ONCY) ("Oncolytics" or the "Company"), a clinical-stage immunotherapy company developing pelareorep, today announced the appointment of John McAdory as Executive Vice President of Strategy and Operations and Yujun Wu as Vice President, Head of Biostatistics. These appointments are expected to enhance the Company's operational, clinical, and regulatory capabilities as Oncolytics advances registration-directed development programs in pancreatic, colorectal, and anal cancers. Mr. McAdory will oversee clinical development execution, operational strategy, and regulatory readiness across the Company's portfolio. He br

    1/14/26 9:00:00 AM ET
    $CGON
    $ONCY
    $TAK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    Fast-Tracking the $537B Cancer Cure: How Accelerated Approvals Reshaping Oncology in 2026

    Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, Jan. 12, 2026 /PRNewswire/ -- USANewsGroup.com News Commentary – The oncology landscape is entering a high-velocity regulatory phase as genomics in cancer care expands toward a projected $69.16 billion by 2032[1]. This massive growth is driven by the systematic integration of genotype-directed treatment pathways into standard medical practice. The precision medicine market is now on a trajectory to expand from $138.67 billion in 2026 to over $537.17 billion by 2035[2]. This strategic pivot toward registration-ready precision assets fuels the 2026 investment case for Oncolytics Biotech Inc. (NASDAQ:ONCY), CG Oncology (NASDAQ:CGON), Ze

    1/12/26 10:35:00 AM ET
    $AVBP
    $CGON
    $ONCY
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    CG Oncology Provides Updated Timeline for PIVOT-006 Phase 3 Topline Data in Intermediate-Risk NMIBC

    - PIVOT-006 Phase 3 topline data evaluating cretostimogene monotherapy for intermediate-risk NMIBC now expected in 1H 2026, nearly one year ahead of schedule - First randomized registrational trial to evaluate an investigational therapy in intermediate-risk NMIBC IRVINE, Calif., Jan. 09, 2026 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ:CGON) today announced an expedited timeline for the topline data readout now expected in the first half of 2026 for the Phase 3 PIVOT-006 clinical trial comparing adjuvant intravesical cretostimogene grenadenorepvec versus surveillance in patients with intermediate-risk non-muscle invasive bladder cancer (IR NMIBC). PIVOT-006 is the first Phase 3 randomi

    1/9/26 8:30:00 AM ET
    $CGON
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $CGON
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Liu Brian Guan-Chyun bought $49,999,983 worth of shares (1,515,151 units at $33.00) (SEC Form 4)

    4 - CG Oncology, Inc. (0001991792) (Issuer)

    9/15/25 8:32:19 AM ET
    $CGON
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Decheng Capital Global Life Sciences Fund Iv, L.P. bought $7,600,000 worth of shares (400,000 units at $19.00) (SEC Form 4) (Amendment)

    4/A - CG Oncology, Inc. (0001991792) (Issuer)

    4/9/24 7:08:23 PM ET
    $CGON
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $CGON
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Wedbush initiated coverage on CG Oncology with a new price target

    Wedbush initiated coverage of CG Oncology with a rating of Outperform and set a new price target of $70.00

    12/11/25 8:19:48 AM ET
    $CGON
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Truist initiated coverage on CG Oncology

    Truist initiated coverage of CG Oncology with a rating of Buy

    11/24/25 8:30:31 AM ET
    $CGON
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Guggenheim initiated coverage on CG Oncology with a new price target

    Guggenheim initiated coverage of CG Oncology with a rating of Buy and set a new price target of $90.00

    10/8/25 8:32:13 AM ET
    $CGON
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $CGON
    Leadership Updates

    Live Leadership Updates

    View All

    Oncolytics Biotech® Appoints John McAdory as EVP of Strategy and Operations and Yujun Wu to Lead Biostatistics

    SAN DIEGO, Jan. 14, 2026 (GLOBE NEWSWIRE) -- Oncolytics Biotech® Inc. (NASDAQ:ONCY) ("Oncolytics" or the "Company"), a clinical-stage immunotherapy company developing pelareorep, today announced the appointment of John McAdory as Executive Vice President of Strategy and Operations and Yujun Wu as Vice President, Head of Biostatistics. These appointments are expected to enhance the Company's operational, clinical, and regulatory capabilities as Oncolytics advances registration-directed development programs in pancreatic, colorectal, and anal cancers. Mr. McAdory will oversee clinical development execution, operational strategy, and regulatory readiness across the Company's portfolio. He br

    1/14/26 9:00:00 AM ET
    $CGON
    $ONCY
    $TAK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    CG Oncology Announces New Board Member and Board Transition

    - Appoints Accomplished Life Sciences Executive Christina Rossi to its Board of Directors - IRVINE, Calif., Nov. 26, 2025 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ:CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients with bladder cancer, today announced the appointment of Christina Rossi to its Board of Directors. Additionally, Simone Song, Senior Partner, ORI Capital, has resigned from the Board effective November 22, 2025. "We are at a critical juncture in CG Oncology's history with our recent BLA initiation for cretostimogene. Now we are laying the foundation for a successful

    11/26/25 7:00:00 AM ET
    $CGON
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Cancer Rates Are Surging in Young Adults -- Here's Where the Smart Money Is Going

    USA News Group News Commentary Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, June 18, 2025 /PRNewswire/ -- USA News Group News Commentary – According to a recent report in Newsweek, more Americans younger than 50 are getting cancer. In fact, the report cites a recent study from the National Institutes of Health (NIH), which found that between 2010 and 2019, more than 2 million Americans aged 15 to 49 were diagnosed with cancer, with early-onset cases rising significantly in 14 different cancer types, including breast, colorectal, and kidney cancers. The dire statistics from the study come at a time where Bloomberg has recently reported on the skyrocketing costs of cancer drugs,

    6/18/25 11:19:00 AM ET
    $CATX
    $CGON
    $GALT
    Medical/Dental Instruments
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)
    Biotechnology: Pharmaceutical Preparations

    $CGON
    Financials

    Live finance-specific insights

    View All

    CG Oncology Announces Best-in-Disease Durability Data in BOND-003 Cohort C and Promising Early Signal in Cohort P for Cretostimogene Grenadenorepvec at the American Urological Association Annual Meeting

    - Robust 24-month complete response rate of 42.3% by K-M for cretostimogene monotherapy in BOND-003 Cohort C – - 58.3% of patients showed durable complete responses by K-M at 24 months – - 97.3% of all treated patients remained free from progression to MIBC at 24 months– - 91.6% of responders remained cystectomy-free at 24 months – - No Grade 3 or greater treatment-related adverse events or deaths reported – - Strong initial Cohort P data reported 90.5% high-grade recurrence-free survival at 3 and 9 months by K-M – - Company will host a conference call and webcast at 8 a.m. EDT on Monday, April 28, 2025 - IRVINE, Calif., April 26, 2025 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ:C

    4/26/25 4:10:03 PM ET
    $CGON
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    CG Oncology to Host Conference Call and Webcast on BOND-003 Data on Monday, April 28, 2025

    IRVINE, Calif., April 24, 2025 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ:CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients with bladder cancer, today announced it will host a conference call and live webcast at 8:00 am ET on April 28, 2025, to discuss results from the Phase 3 BOND-003 trial of cretostimogene monotherapy in high-risk BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) to be presented on April 26, 2025, at a Plenary Session at the American Urological Association (AUA) Annual Meeting in Las Vegas, Nevada. Individuals can access the webcast via the link on

    4/24/25 8:00:00 AM ET
    $CGON
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    CG Oncology Reports 2024 Year End Financial Results and Provides Business Updates

    - Cretostimogene Monotherapy Demonstrated Sustained, Durable Complete Responses in High-Risk Bacillus Calmette Guérin (BCG)-Unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC) - - Initiated CORE-008 Clinical Trial of Cretostimogene Monotherapy in High-Risk BCG-Naïve (Cohort A) and BCG-Exposed (Cohort B) NMIBC - - Late-Breaking Clinical and First Translational Data from BOND-003 Cohort C Presented at the 40th Annual European Association of Urology Congress - - Completed Oversubscribed $238 Million Follow-on Public Equity Offering that Extends Expected Runway into the First Half of 2028 - IRVINE, Calif., March 28, 2025 (GLOBE NEWS

    3/28/25 7:00:00 AM ET
    $CGON
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $CGON
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by CG Oncology Inc.

    SC 13G/A - CG Oncology, Inc. (0001991792) (Subject)

    11/12/24 2:30:47 PM ET
    $CGON
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by CG Oncology Inc.

    SC 13G/A - CG Oncology, Inc. (0001991792) (Subject)

    11/4/24 10:22:51 AM ET
    $CGON
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G filed by CG Oncology Inc.

    SC 13G - CG Oncology, Inc. (0001991792) (Subject)

    7/22/24 4:35:57 PM ET
    $CGON
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care